Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028 Study 1 of Essential3 program for ulixacaltamide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback